Shanghai Haohai Biological Technology Co., Ltd. (“Haohai Biotec”) filed a Next Day Disclosure Return for 6 May 2026, confirming no change to its aggregate issued share capital while detailing the latest progress under its share-repurchase programme.

Key figures

• Total issued shares (excluding treasury shares) unchanged at 226.13 million, comprising 190.20 million A-shares and 35.93 million H-shares.

H-share buyback on 6 May 2026

• Shares repurchased: 85,200

• Price range: HKD 21.60–22.12

• Aggregate consideration: HKD 1.87 million

Cumulative H-shares pending cancellation

• Including the latest transaction, 777,200 H-shares bought since 23 March 2026 are awaiting cancellation, equating to approximately 2.16 % of the current H-share float and 0.34 % of the company’s total issued shares.

Repurchase mandate utilisation

• Authorised under the 10 June 2025 mandate: up to 3.91 million shares.

• Shares repurchased to date under the mandate: 3.38 million, representing 8.63 % of the issued share base on the mandate date.

• Moratorium on new share issues following the latest repurchase runs through 5 June 2026, in line with Hong Kong listing rules.

A-share position

• A-share figures remain unchanged at 190.20 million issued shares and 3.85 million held in treasury. No A-share repurchases are outstanding.

The company confirms that all buybacks have complied with Hong Kong Stock Exchange regulations and relevant domestic rules.